PMID- 23209815
OWN - NLM
STAT- MEDLINE
DCOM- 20130522
LR  - 20220311
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 11
DP  - 2012
TI  - Fascin-1, ezrin and paxillin contribute to the malignant progression and are 
      predictors of clinical prognosis in laryngeal squamous cell carcinoma.
PG  - e50710
LID - 10.1371/journal.pone.0050710 [doi]
LID - e50710
AB  - AIMS: Fascin-1, ezrin and paxillin, cytoskeleton-associated proteins, have been 
      implicated in several human cancers, but their role in laryngeal squamous cell 
      carcinoma (LSCC) is unknown. We investigated the association of their expression 
      and clinicopathologic factors and their prognostic value in LSCC. MATERIALS AND 
      METHODS: Quantitative RT-PCR and western blot analyses were used to examine mRNA 
      and protein levels in 10 fresh LSCC specimens and 10 corresponding adjacent 
      normal margin (ANM) tissues from patients undergoing surgery in 2012. We used 
      immunohistochemistry to retrospectively study 216 paraffin blocks of LSCC samples 
      from patients (193 men) who had undergone surgery between 2000 and 2006 and had 
      not received special treatment before the diagnosis. Univariate analysis of 
      patient survival involved the Kaplan-Meier method. Multivariate analyses involved 
      the Cox proportional hazards model. RESULTS: The relative mRNA and protein levels 
      of fascin-1, ezrin and paxillin were significantly greater in LSCC than ANM 
      tissue (P<0.05). The high expression of fascin-1, ezrin or paxillin was 
      positively correlated with poor tumor differentiation, cervical lymph node 
      metastasis (N+), and advanced clinical stage (III+IV) (P<0.05) but not sex or 
      metastasis. In addition, a high expression of fascin-1 (P = 0.007) or ezrin 
      (P = 0.047) was associated with advanced tumor stage (T3+T4). The expression of 
      fascin-1 was higher in smokers than non-smokers (P = 0.019). A high expression of 
      fascin-1, ezrin or paxillin was associated with poor prognosis. CONCLUSIONS: 
      Fascin-1, ezrin and paxillin may be prognostic of poor outcome with LSCC after 
      surgery. Our study may lead to establishing new molecular therapeutic targets 
      and/or prognostic biomarkers in LSCC.
FAU - Gao, Wei
AU  - Gao W
AD  - Department of Otolaryngology, Head & Neck Surgery, No. 1 Hospital, Shanxi Medical 
      University, Taiyuan, Shanxi, China.
FAU - Zhang, Chunming
AU  - Zhang C
FAU - Feng, Yan
AU  - Feng Y
FAU - Chen, Ganggang
AU  - Chen G
FAU - Wen, Shuxin
AU  - Wen S
FAU - Huangfu, Hui
AU  - Huangfu H
FAU - Wang, Binquan
AU  - Wang B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121127
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Carrier Proteins)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (Microfilament Proteins)
RN  - 0 (Paxillin)
RN  - 0 (ezrin)
RN  - 146808-54-0 (fascin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blotting, Western
MH  - Carcinoma, Squamous Cell/*metabolism/*pathology
MH  - Carrier Proteins/genetics/*metabolism
MH  - Cytoskeletal Proteins/genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*metabolism/*pathology
MH  - Male
MH  - Microfilament Proteins/genetics/*metabolism
MH  - Middle Aged
MH  - Paxillin/genetics/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Young Adult
PMC - PMC3507730
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2012/12/05 06:00
MHDA- 2013/05/23 06:00
PMCR- 2012/11/27
CRDT- 2012/12/05 06:00
PHST- 2012/06/04 00:00 [received]
PHST- 2012/10/24 00:00 [accepted]
PHST- 2012/12/05 06:00 [entrez]
PHST- 2012/12/05 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
PHST- 2012/11/27 00:00 [pmc-release]
AID - PONE-D-12-16075 [pii]
AID - 10.1371/journal.pone.0050710 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(11):e50710. doi: 10.1371/journal.pone.0050710. Epub 2012 Nov 27.